Measures to reduce the Transmission of Creutzfeldt-Jakob Disease and Variant Creutzfeldt-Jakob Disease

This draft guidance is intended to amend the guidance entitled "Guidance for Industry: Revised Preventive Measures to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease (CJD) and Variant Creutzfeldt-Jakob Disease (vCJD) by Blood and Blood Products," dated May 2010 (2010 CJD/vCJD guidance)(May 27, 2010),1 by revising the recommendations for labelling of plasma-derived products, including albumin and products containing plasma-derived albumin, to reflect current understanding of vCJD transmission through blood. When finalized, the 2010 CJD/vCJD guidance will be updated by incorporating the revised labelling recommendations. However, other recommendations in the 2010 CJD/vCJD guidance will continue to be valid as provided.

For further information please see "Draft Guidance for Industry: Amendment to “Guidance for Industry: Revised Preventive Measures to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease and Variant Creutzfeldt-Jakob Disease by Blood and Blood Products”.

Cookies help us in providing our services. By using our services, you agree that we use cookies. Further information

OK

Go back

GMP Conferences by Topics

Cookies help us in providing our services. By using our services, you agree that we use cookies. Further information

OK